Jon A Arnason, MD | |
451 Junction Rd, Madison, WI 53717-2656 | |
(608) 263-7577 | |
(608) 262-3735 |
Full Name | Jon A Arnason |
---|---|
Gender | Male |
Speciality | Rheumatology |
Experience | 37 Years |
Location | 451 Junction Rd, Madison, Wisconsin |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265760433 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RR0500X | Internal Medicine - Rheumatology | 33052 (Wisconsin) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Wi Hospitals & Clinics Authority | Madison, WI | Hospital |
Meriter Hospital | Madison, WI | Hospital |
Richland Hospital | Richland center, WI | Hospital |
Divine Savior Healthcare | Portage, WI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Wisconsin Medical Foundation Inc | 6608785464 | 2164 |
News Archive
Forget New Year's; a study published today in the Journal of the American Medical Association, Internal Medicine found that Mondays are when smokers are most likely to think about quitting.
Today the U.S. House of Representatives passed the "Improving Access to Clinical Trials Act" (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a final study report to the U.S. Food & Drug Administration (FDA) for a completed, six-month histological study examining skin after injections of azficel-T.
While immunotherapy - a form of treatment that uses the body's immune system to recognize, attack and kill tumor cells - has given hope to people across the globe, it fails in a significant proportion of cancer patients.
› Verified 7 days ago
Entity Name | University Of Wisconsin Medical Foundation Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
Forget New Year's; a study published today in the Journal of the American Medical Association, Internal Medicine found that Mondays are when smokers are most likely to think about quitting.
Today the U.S. House of Representatives passed the "Improving Access to Clinical Trials Act" (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a final study report to the U.S. Food & Drug Administration (FDA) for a completed, six-month histological study examining skin after injections of azficel-T.
While immunotherapy - a form of treatment that uses the body's immune system to recognize, attack and kill tumor cells - has given hope to people across the globe, it fails in a significant proportion of cancer patients.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Jon A Arnason, MD 7974 Uw Health Ct, Middleton, WI 53562-5531 Ph: () - | Jon A Arnason, MD 451 Junction Rd, Madison, WI 53717-2656 Ph: (608) 263-7577 |
News Archive
Forget New Year's; a study published today in the Journal of the American Medical Association, Internal Medicine found that Mondays are when smokers are most likely to think about quitting.
Today the U.S. House of Representatives passed the "Improving Access to Clinical Trials Act" (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a final study report to the U.S. Food & Drug Administration (FDA) for a completed, six-month histological study examining skin after injections of azficel-T.
While immunotherapy - a form of treatment that uses the body's immune system to recognize, attack and kill tumor cells - has given hope to people across the globe, it fails in a significant proportion of cancer patients.
› Verified 7 days ago
Prof. Marvin Lyle Birnbaum, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3330 University Ave, Suite 300, Madison, WI 53705 Phone: 608-263-9641 Fax: 608-265-4429 | |
Yingyu Gao, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6400 | |
Dr. Sam Joseph Lubner, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-265-1700 | |
Randy S Heidel, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 20 S Park St, Madison, WI 53715 Phone: 608-287-2250 Fax: 608-287-2438 | |
Benjamin Kleiber, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 700 S Park St, Dean & St. Mary's Outpatient Center, Madison, WI 53715 Phone: 608-260-2900 Fax: 608-260-2956 | |
N Thomas Casper, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3102 Meriter Way, Madison, WI 53719 Phone: 608-417-8800 | |
Philip Tepper Cohen, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 5154 Juneau Rd, Madison, WI 53705 Phone: 608-441-2512 Fax: 608-441-2512 |